Webinars and Sponsored Roundtables — Register Now

Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.

Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

2018 Issues

Anatomic Pathology Abstracts

June 2018—Impact of pattern of invasion in invasive endocervical adenocarcinoma; Inflammatory myofibroblastic tumor of the uterus: an analysis of 13 cases.

Molecular Pathology Abstracts

June 2018—Genetics and pathogenesis of diffuse large B-cell lymphoma: Understanding the genetic basis of diffuse large B-cell lymphoma is important for understanding the pathogenesis of the disease and the molecular attributes that may influence therapeutic response.

Newsbytes

June 2018—Electronic device shows promise for identifying pathology specimens: While barcodes and radio-frequency identification are considered the workhorses of pathology specimen identification, a new technology, nearly two decades in the making, may soon get a piece of the action.

Put It on the Board

June 2018—FDA clears T2Bacteria panel for detecting sepsis-causing pathogens: T2 Biosystems received market clearance from the Food and Drug Administration for the T2Bacteria panel for the direct detection of bacterial species in human whole blood specimens from patients with suspected bloodstream infections.

Letters

June 2018—LCIS variants and DCIS: We write in response to the article by Karen Lusky regarding tips to distinguish DCIS from variant forms of LCIS (April 2018). A different question might be: Is it actually important to distinguish these two in situ proliferations?

From the President’s Desk—CAP18: bringing it all back home

June 2018—Nobody has an annual meeting like ours. Nobody. And CAP18 will be no exception. The CAP18 educational program features 85 courses presented by 128 outstanding faculty. A quick scan of the program reveals 42 new learning opportunities and another 38 returning by popular demand.

Skirting the pitfalls of merging lab results

May 2018—“One of these things is not like the others” is a fun puzzle for kids in the context of Sesame Street. But it can be a vexing informatics challenge when you are managing data entered in fields in a database. For anyone charged with merging outside laboratory results into an institution’s electronic health record alongside results from an in-house laboratory, the differences can generate no end of headaches.

New contender speeds ID with susceptibility testing

May 2018—If a seismic shift were to happen in microbiology, the technology behind the Accelerate Pheno system and PhenoTest BC test kit, which won FDA approval last year as a rapid pathogen identification and antimicrobial susceptibility testing (AST) system for blood cultures, could well be the cause.

Teaming up: how one site is managing its complex liver cases

May 2018—It didn’t take long for Heather Stevenson-Lerner, MD, PhD, to grasp one key fact about the liver biopsy cases she was seeing at the University of Texas Medical Branch, Galveston: They were often complicated. UTMB sees plenty of challenging liver cases of its own, says Dr. Stevenson-Lerner, assistant professor of medicine and liver and transplantation pathologist, Department of Pathology.

Pharmacogenomics advocates make case for wider use

May 2018—Use of pharmacogenomic testing is still limited, despite ample research, the existence of guidelines, and the emerging evidence it can help patients. Panels can be costly and insurance coverage variable, and providers need guidance—from pharmacists, the lab, decision support alerts—in knowing what and when to order and in understanding the results. Plus, patients move.